to Content
Header Image

07: Pharmacogenomics: Current State and Future Perspectives

Seminar / Seminar
english language

Patients expect optimal treatment with effective drugs. Currently, safety and efficacy of drugs are suboptimal. The knowledge of the human genome sequence and its individual variation increasingly enables medicine to assess the individual risk to acquire a particular disease, raises the number and specificity of drug targets, and explains variation in the efficacy and toxicity of drugs. Today, pharmacogenetic tests are already used for specific applications, e.g. prior to chemotherapy in childhood leukaemia. In the future, pharmacogenomic findings will affect the choice and dose of drugs and will influence drug discovery. These developments have societal, ethical and economic consequences which shall be discussed in the seminar.

Medical University of Vienna
University of Basel

Dipl.-Ing. Dr. Christine MANNHALTER

Medical University of Vienna

Biotechnology at the University of Life Sciences and Natural Resources Masters Thesis Ph. D. Graduate Student, University Vienna Medical School, Department of Haematology and Haemostaseology Postdoctoral Fellowship with Dr. Sandra Schiffman, University of Southern California, School of Medicine, Haematology Division, Los Angeles, California , 1983 Visiting Research Associate at the University of Southern California, Los Angeles (3 months each) Training in Application of Gene Analysis for the Diagnosis of Haemophilia A and B with Dr. Ian Peake, Cardiff, UK Research Assistant at the First Department of Medicine, University Vienna Medical School Habilitation Assistant Professor at the same institution tit. Ao. Univ. Prof. Associate Professor at the same institution Associate Professor at the Department of Laboratory Medicine, University Vienna Medical School

Dr. Urs A. MEYER

University of Basel

 Urs A. Meyer is Professor of Pharmacology and Chairman of the Division of Pharmacology/Neurobiology at the Biozentrum of the University of Basel and its Medical School, Basel, Switzerland. He also is a consultant physician in the Outpatient Clinic of the Department of Medicine of the University Hospital in Basel. Urs A. Meyer received his M.D. degree from the University of Zürich in 1967 and subsequently was an intern and resident in internal medicine at the University of California, San Francisco. From 1969 to 1971 he was a postdoctoral fellow in Clinical Pharmacology and Hepatology and from 1972 to 1975 an assistant professor in clinical pharmacology at the University of California, San Francisco. Urs A. Meyer then returned to Switzerland as Chief of the Division of Clinical Pharmacology of the University of Zürich Medical School and in 1983 was appointed to his present position as Professor and Chairman at the University of Basel. Research interests have included the study of genetic and environmental factors that determine individual drug response with special emphasis on pharmacogenetic conditions. In particular, Urs A. Meyer has studied experimental and clinical porphyrias and has used a large human liver bank to predict drug metabolism patterns of new drugs and to study the molecular mechanisms of environmental and genetic factors influencing drug metabolizing enzymes. His laboratory has been involved in the cloning and characterization of numerous human genes controlling drug-metabolizing enzymes, i.e. microsomal epoxide hydrolase, several cytochromes P450 (CYP2D6, 2C9, 2C19), N-acetyltransferases, and has elucidated several genetic polymorphisms of human drug response at the molecular level. More recently, his laboratory has made major contributions to the molecular events that lead to induction of drug metabolism. The contributions of Urs A. Meyer are recognized in the ISI Highly Cited Researcher Database (


show timetable